Community-directed, ivermectin-treatment programmes for onchocerciasis control in Uganda: the selection and validation of indicators for monitoring sustainability at the district level.
The selection and validation of indicators for predicting and monitoring sustainment in community-directed, ivermectin-treatment programmes (CDITP) at the community level in the Kabale, Kisoro and Rukungiri districts of Uganda have already been reported. The aim of the present study was to select and validate similar indicators at the district level, in the same districts over the same 4-year period. Three dependent-variable scales of programme sustainability (PS), PS1, PS2 and PS3, were compared by district. As at the community level, Rukungiri district clearly performed better than Kabale or Kisoro. Cost variables compiled at the district level and the ratios of numbers of community-based distributors (CBD) to community members were used as input variables in regression and correlation models, with PS1, PS2, and PS3 as outcome variables. In the regression model, cost of training CBD was found to be statistically significant (P = 0.0186). This variable also scored 100% on a scale for programme-indicator sensitivity and hence was selected as a helpful indicator. In the correlation model, cost of health education of community members had a weak relationship with PS1 (P = 0.0662). Cost of training CBD had a significant negative correlation with PS2 (P = 0.0186), indicating that reducing the cost of training would facilitate sustainability. PS3 showed weak negative correlations with cost of health education of community members (P = 0.0586) and cost/person treated in the district (P = 0.0584). Sustainment of CDITP might be better, therefore, if the costs per person could be reduced. As correlation relationships may not be linear, however, they were not considered particularly useful in the selection of helpful indicators.
Katabarwa
M N
MN
Global 2000, River Blindness Program, Uganda. rvbprg@starcom.co.ug
Mutabazi
D
D
D003153:Community Health Services / Q000458:organization & administration* / Q000592:standards; D019468:Disease Management; D005369:Filaricides / Q000627:therapeutic use*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use*; D009855:Onchocerciasis / Q000453:epidemiology / Q000517:prevention & control*; D015397:Program Evaluation; D014454:Uganda / Q000453:epidemiology
D005369:Filaricides; D007559:Ivermectin